Insilico Medicine and Bora Pharmaceuticals Launch Strategic Alliance to Build a Next-Generation Drug Innovation Model

Today, on the opening day of BIO Asia–Taiwan 2026, Insilico Medicine (“Insilico”; HKEX: 3696) and Bora Pharmaceuticals Co., Ltd.  (“Bora”; TWSE: 6472; OTCQX: BORAY) announced a strategic alliance to build a next-generation drug innovation model by combining AI-powered drug discovery with global development and manufacturing capabilities. The collaboration creates an integrated pathway across the pharmaceutical value chain, from computational discovery and clinical development to manufacturing and commercial supply. The two parties will establish a multi-faceted collaboration framework, with further details to be finalized in future agreements. If fully implemented, the collaboration could exceed US$2.5 billion in potential value.

Where AI Drug Discovery Meets Global Development and Manufacturing

By combining Insilico’s AI-driven drug discovery platform with Bora’s global development and manufacturing capabilities, the partnership seeks to establish a next-generation drug innovation model that bridges computational discovery with end-to-end pharmaceutical development. Beyond a conventional licensing or CDMO agreement, the alliance represents a broader shift toward integrating AI-powered innovation with the infrastructure required to advance medicines from discovery to commercialization.

Bobby Sheng, founder, Chairman of Bora Group and CEO of Bora Pharmaceuticals, stated that Insilico Medicine has demonstrated that generative AI can effectively identify novel targets, design new molecules, and advance drug candidates into clinical development, highlighting its leadership in AI-driven drug discovery.

“By combining Insilico’s native AI capabilities with Bora’s global expertise across formulation development, CMC, regulatory submissions, scale-up manufacturing, quality management, commercial manufacturing, supply chain, and market commercialization, we aim to build an end-to-end AI platform that connects the entire drug innovation value chain—from discovery to commercialization—providing integrated solutions for customers and partners,” said Sheng. He added that the collaboration represents a key step in Bora’s transformation strategy, evolving the company from a drug development and manufacturing partner into a more comprehensive pharmaceutical innovation ecosystem.

Alex Zhavoronkov, Ph.D., Founder, Co-CEO, and Chief Business Officer of Insilico Medicine, said: “We are thrilled to partner with Bora, a forward-looking industry leader with world-class development and manufacturing capabilities and a strong commitment to AI-driven innovation. This collaboration further strengthens Insilico’s partnerships in cutting-edge innovation across the Asia-Pacific region. By integrating Insilico’s proprietary AI-native engine, which spans target discovery, generative chemistry, and molecular optimization, with Bora’s development, manufacturing, and commercialization capabilities, we look forward to driving broad AI transformation. Together, we will demonstrate the speed, efficiency, and scalability potential of AI-powered drug discovery.”

Insilico will contribute AI-based approaches for target identification and molecular design, while Bora provides expertise across process development, clinical manufacturing, and global commercial supply. Together, the companies create an integrated pathway designed to accelerate the translation of AI-generated insights into therapeutic products.

As AI-driven biotech companies advance toward clinical and commercial development, they increasingly seek partners that can bridge discovery, development, and manufacturing expertise. This collaboration highlights an emerging industry model in which AI-powered platforms work alongside global development infrastructure to accelerate the journey from early innovation to clinical-stage and commercialized medicines.

Insilico Medicine’s AI-Powered Drug Discovery Ecosystem

Insilico enters the partnership with Bora as one of the industry’s most active AI-driven drug discovery companies, combining a proprietary AI platform, automated laboratory infrastructure, and a growing clinical pipeline with an expanding global collaboration network.

Since the beginning of 2026, the company has significantly expanded its business through out-licensing, co-development, and research collaborations with global pharmaceutical and biotechnology partners, including Servier, Eli Lilly (up to $2.75 billion), SK Biopharmaceuticals (up to $2.5 billion), Qilu Pharmaceutical, CMS, Menarini, Hisun Pharma, Takeda (up to $600 million), and so on. Beyond new partnerships, Insilico has also achieved multiple development milestones across existing collaborations, enhancing both the commercial validation of its AI platform and the sustainability of its long-term alliance strategy.

At the core of Insilico’s innovation engine is Pharma.AI, anchored by its Biology42, Chemistry42, and Science42 platforms. Throughout 2026, the company further expanded its AI capabilities with the launch of PandaClaw, an agentic system that automates biological analysis and bioinformatics workflows, and LabClaw, an autonomous laboratory orchestration platform designed to coordinate experimental workflows across its Life Star2 robotic laboratory. Together, these technologies accelerate the translation of AI-generated hypotheses into experimental validation.

Insilico has also continued to strengthen its Pharmaceutical Superintelligence (PSI) strategy through Science MMAI Gym, a foundation model training framework purpose-built for life sciences. Integrating more than 1,000 drug discovery benchmarks and approximately 120 billion pharmaceutical data tokens, the platform is designed to enhance scientific reasoning and task execution across biology, chemistry, and drug discovery. Recent collaborations with Liquid AI and Human Longevity further extend this AI infrastructure, while strategic partnerships with Microsoft Azure and Google Cloud provide scalable computing resources to support next-generation drug development.

The company’s AI capabilities are increasingly reflected in clinical execution. Its lead candidate, Rentosertib (formerly ISM001-055), recently became the world’s first AI-discovered and AI-designed drug to advance into Phase III clinical trials (NCT07687459). The drug targets Traf2- and NCK-interacting kinase (TNIK) to treat idiopathic pulmonary fibrosis (IPF).

As of June 30, 2026, Insilico’s pipeline comprised 31 nominated preclinical candidates, including 13 IND-cleared programs and 10 clinical-stage assets, reflecting its evolution from an AI technology provider into a fully integrated biotechnology company capable of discovering, developing, and advancing novel therapeutics alongside global partners.

Bora Pharmaceuticals’ Global Platform for Drug Development and Manufacturing

Bora contributes to the partnership a rapidly expanding global development and manufacturing platform with integrated capabilities spanning formulation development, clinical and commercial manufacturing, packaging, and worldwide supply. Through its network across the United States, Canada and Taiwan, Bora supports pharmaceutical products from early development through commercial production, providing end-to-end solutions across the drug development lifecycle.

Over the past two years, Bora has accelerated its global expansion through strategic acquisitions and capacity investments. These efforts have strengthened its North American presence while expanding its capabilities across commercial manufacturing, biologics development, and global supply.

One of the key milestones in Bora’s global expansion was its US$122.5 million acquisition of MacroGenics’ GMP manufacturing operations through its wholly owned subsidiary Bora Biologics USA, LLC, including a biologics drug substance facility in Rockville, Maryland, and an associated warehousing center in Frederick, Maryland. Following the acquisition, Bobby Sheng, Chairman and CEO of Bora Group, noted the deal establishes a US-based biologics manufacturing platform supporting sponsors from development through commercial supply.

“As regulatory and supply chain dynamics continue to evolve, we expect biotech and pharmaceutical companies to increasingly seek manufacturing partners with US-based, inspection-proven infrastructure,” Sheng said. “Bora Biologics is designed to meet this need, offering an integrated, end-to-end biologics platform spanning drug substance and drug product capabilities.”

Following the transaction, Bora Biologics now operates 20,000 liters of single-use bioreactor drug substance manufacturing capacity across two US sites in Rockville, Maryland, and San Diego, California, along with a development facility in Zhubei, Taiwan. The addition of the Rockville facility expands Bora Biologics’ biologics CDMO capabilities, strengthening its capacity in drug substance manufacturing and integrated analytical services.

Unlike Insilico’s previous collaborations, which primarily centered on AI-enabled drug discovery with pharmaceutical companies, the Bora partnership extends into manufacturing and commercialization, making it one of the company’s first publicly announced strategic alliances with a global CDMO.

Author

Steven Chung

紅杏枝頭春意鬧固然是眾人所追求的風景，但我願意說，青蘿拂行衣更能湧生感嘆。 願在海量晦澀的生醫資訊中，為您點亮一座心燈塔。鐘煌翔